Palatin Technologies, Inc. (PTN)
NYSEAMERICAN: PTN · Real-Time Price · USD
1.150
+0.040 (3.60%)
Dec 30, 2024, 4:00 PM EST - Market closed
Palatin Technologies Employees
Palatin Technologies had 30 employees as of June 30, 2024. The number of employees decreased by 4 or -11.76% compared to the previous year.
Employees
30
Change (1Y)
-4
Growth (1Y)
-11.76%
Revenue / Employee
$79,470
Profits / Employee
-$1,078,459
Market Cap
22.48M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 122,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 89,900 |
| Novartis AG | 76,057 |
| Merck & Co. | 72,000 |
| Novo Nordisk | 64,319 |
PTN News
- 11 days ago - Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy - PRNewsWire
- 14 days ago - Palatin Announces Exercise of Warrants for Approximately $3.4 Million Gross Proceeds - PRNewsWire
- 5 weeks ago - Palatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative Colitis - PRNewsWire
- 6 weeks ago - Palatin Technologies, Inc. (PTN) Q1 2025 Earnings Conference Call Transcript - Seeking Alpha
- 6 weeks ago - Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results - PRNewsWire
- 7 weeks ago - Palatin to Report First Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on November 14, 2024 - PRNewsWire
- 2 months ago - Palatin Presents Data on Novel Melanocortin 4 Receptor Selective Oral Small Molecule PL7737 Obesity Program at ObesityWeek® 2024 - PRNewsWire
- 2 months ago - Palatin Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (MC4R Agonist) Co-Administered with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity - PRNewsWire